Dr Lalchandani Labs Ltd Rights Issue 2026
ClosedDr Lalchandani Labs Ltd Rights Issue Details
| Issue Size (Shares) | 43,32,000 | Issue Size (Amount) | - |
|---|---|---|---|
| Issue Price | ₹10.00 per share | Face Value | ₹10.00 per share |
| Terms of Payment | The entire Issue Price of Rs.10/- per share is payable on Application. |
Listing At | - |
| Ratio | 1:1 | Issue Size (₹ Crores) | ₹4.33 |
Dr Lalchandani Labs Limited is a New Delhi–based diagnostic healthcare company that delivers a wide spectrum of pathology and medical testing services. Operating through a well-established network of laboratories and sample collection centers across the Delhi/NCR region, the company plays an important role in supporting preventive, diagnostic, and clinical healthcare needs.
The lab offers comprehensive diagnostic solutions spanning biochemistry, hematology, microbiology, virology, genetic testing, routine and specialized health checkups, corporate wellness packages, and blood bank services. With a strong focus on accuracy, quality assurance, and timely reporting, Dr Lalchandani Labs leverages advanced diagnostic equipment and standardized processes to ensure reliable results for patients and healthcare professionals alike.
Built on the foundation of a legacy pathology practice and supported by NABL-accredited facilities, the company serves individuals, hospitals, clinics, and other healthcare providers. Its commitment to quality standards, technological advancement, and patient-centric service has positioned Dr Lalchandani Labs as a trusted name in diagnostic healthcare within the Delhi/NCR ecosystem.
Dr Lalchandani Labs Ltd Rights Issue Timetable
| Last Date to buy shares | Fri, Jan 23, 2026 | Record Date | Tue, Jan 27, 2026 |
|---|---|---|---|
| Credit of Rights Entitlements | Mon, Feb 02, 2026 | Bid/Offer Opens On | Wed, Feb 04, 2026 |
| Renunciation of Rights Entitlements | Tue, Feb 17, 2026 | Bid/Offer Closes On | Fri, Feb 20, 2026 |
| Deemed Date of Allotment | Mon, Feb 23, 2026 | Credit Date | Tue, Feb 24, 2026 |
| Listing Date | Wed, Feb 25, 2026 | ||
Company Financials
Company Financials (Restated Consolidated)
| Period Ended | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|
| Total Income | 4.46 | 5.05 |
| Profit After Tax | 0.40 | 0.62 |
| Reserves and Surplus | 5.62 | 5.21 |
Objects of the Issue
The Company proposes to utilize the Net Proceeds from the Issue for the following purposes:
Funding Working Capital Requirements
To meet day-to-day operational needs of the Company, including expenses related to operations, procurement, administration, and other business activities, ensuring smooth and uninterrupted functioning.
Adjustment of Unsecured Loans Against Promoter Entitlement
To adjust or set off certain unsecured loans extended to the Company against the entitlement of the Promoter, thereby strengthening the capital structure and reducing related-party liabilities.
Repayment / Settlement of Certain Outstanding Borrowings
To repay or settle existing borrowings, which will help reduce the Company’s debt burden, improve its balance sheet, and lower interest and financial obligations.
General Corporate Purposes
To meet general business requirements such as brand building, strategic initiatives, business development, administrative expenses, and other corporate needs, providing flexibility to support the Company’s growth and long-term objectives.
Company Contact Information
Dr Lalchandani Labs Ltd
M-20 Basement,
Greater Kailash-1,
South Delhi,
Delhi, 110048
Phone: 9873972036
Email: info@lalchandanipathlab.com
Website: https://lalchandanipathlab.com/
Dr Lalchandani Labs Ltd Rights Issue Registrar
Cameo Corporate Services Ltd.
Phone: +91-44-28460390
Email: priya@cameoindia.com
